Clinical Trials Logo

Clinical Trial Summary

The purposes of this study are:

- To determine the overall response rate of patients treated with at least 2 cycles of this regimen.

- To determine the feasibility and toxicity of the combination of topotecan and docetaxel.


Clinical Trial Description

The main objective of this study was to determine the overall response rate of patients treated with at least 2 cycles of topotecan and docetaxel. The secondary objectives were to determine the feasibility and toxicities of this combination. The final secondary objective is overall survival for patients that received 2 or more cycles.

Methods: Eligible pts with recurrent small cell lung cancer had to be at least 3 months from initial treatment. Pts received Docetaxel 30 mg/m2 IV followed by Topotecan 3 mg/m2 IV Days 1 and 8 of a 21 day cycle. Disease assessment was done every 2 cycles. Toxicity was measured each cycle. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00315211
Study type Interventional
Source Aultman Health Foundation
Contact
Status Terminated
Phase Phase 2
Start date November 2004
Completion date November 8, 2007

See also
  Status Clinical Trial Phase
Completed NCT00199082 - Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults Phase 4
Terminated NCT02499952 - Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Phase 2
Recruiting NCT03521986 - Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS Phase 3